Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Exploratory, Open-Label Study of the Safety and Efficacy of High Dose or High Dosing Frequency Alglucosidase Alfa Treatment in Patients With Pompe Disease Who Do Not Have an Optimal Response to the Standard Dose Regimen

NCT00483379 is registered in ClinicalTrials.gov with Genzyme, a Sanofi Company as lead sponsor.

NCT NCT00483379
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00483379 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Exploratory, Open-Label Study of the Safety and Efficacy of High Dose or High Dosing Frequency Alglucosidase Alfa Treatment in Patients With Pompe Disease Who Do Not Have an Optimal Response to the Standard Dose Regimen
Lead sponsor
Genzyme, a Sanofi Company
Phase
Phase 4
Overall status
Completed
Start date
May 31, 2007
Completion date
July 31, 2010
Enrollment
13 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

glycogen storage disease type ii (gsd-ii), glycogenesis 2 acid maltase deficiency, pompe disease